BRPI0907463A2 - forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias - Google Patents

forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias

Info

Publication number: BRPI0907463A2
Authority: BR; Brazil
Prior art keywords: triazole; inflammatory diseases; polymorphic form; treating inflammatory; pyridine derivative
Prior art date: 2008-02-04

Application number

BRPI0907463A

Other languages

English (en)

Inventor

John Butcher Kennneth

Original Assignee

Pfizer Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-02-04

Filing date

2009-01-28

Publication date

2019-09-24

2009-01-28 Application filed by Pfizer Ltd filed Critical Pfizer Ltd

2019-09-24 Publication of BRPI0907463A2 publication Critical patent/BRPI0907463A2/pt

Links

NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical class C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1
150000003222 pyridines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Hematology (AREA)
Virology (AREA)
Dermatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)

BRPI0907463A 2008-02-04 2009-01-28 forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias BRPI0907463A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2587908P	2008-02-04	2008-02-04
PCT/IB2009/050351 WO2009098612A2 (en)	2008-02-04	2009-01-28	Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases

Publications (1)

Publication Number	Publication Date
BRPI0907463A2 true BRPI0907463A2 (pt)	2019-09-24

Family

ID=40911989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0907463A BRPI0907463A2 (pt)	2008-02-04	2009-01-28	forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias

Country Status (22)

Country	Link
US (1)	US8222273B2 (pt)
EP (1)	EP2303267B1 (pt)
JP (1)	JP5344942B2 (pt)
KR (2)	KR101422318B1 (pt)
CN (1)	CN101939320B (pt)
AR (1)	AR070411A1 (pt)
AU (1)	AU2009211072B2 (pt)
BR (1)	BRPI0907463A2 (pt)
CA (1)	CA2712574C (pt)
CY (1)	CY1114389T1 (pt)
DK (1)	DK2303267T3 (pt)
ES (1)	ES2423991T3 (pt)
IL (1)	IL206948A (pt)
MX (1)	MX2010008535A (pt)
NZ (1)	NZ587094A (pt)
PL (1)	PL2303267T3 (pt)
PT (1)	PT2303267E (pt)
RU (1)	RU2448966C1 (pt)
SI (1)	SI2303267T1 (pt)
TW (1)	TWI391391B (pt)
WO (1)	WO2009098612A2 (pt)
ZA (1)	ZA201005137B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
EP2464346A1 (en)	2010-08-30	2012-06-20	Pulmatrix, Inc.	Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en)	2010-08-30	2015-12-10	Pulmatrix Operating Company, Inc.	Dry powder formulations and methods for treating pulmonary diseases
EP3470057B1 (en)	2010-09-29	2021-11-03	Pulmatrix Operating Company, Inc.	Cationic dry powders comprising magnesium salt
WO2013052844A1 (en)	2011-10-07	2013-04-11	Pulmatrix, Inc.	Methods for treating and diagnosing respiratory tract infections
BR112014013178A2 (pt)	2011-12-09	2017-06-13	Chiesi Farm Spa	composto, composição farmacêutica e uso de um composto
CN105646484A (zh) *	2016-03-01	2016-06-08	孙霖	晶型b及制备方法
CN105693716A (zh) *	2016-03-01	2016-06-22	孙霖	晶型a及制备方法
GB201611712D0 (en)	2016-07-02	2016-08-17	Hvivo Services Ltd	Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en)	2017-12-22	2018-02-07	Hvivo Services Ltd	Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP990182A2 (en)	1998-06-11	2000-02-29	Du Pont Pharm Co	Crystalline efavirenz
JP3784001B2 (ja)	1998-11-20	2006-06-07	三菱化学株式会社	５−［｛６−（２−フルオロベンジル）オキシ−２−ナフチル｝メチル］−２，４−チアゾリジンジオンの結晶体
CN1878741A (zh) *	2004-07-16	2006-12-13	Usv有限公司	阿扎伐醌的新颖多晶形物及其制备方法
PL1778686T3 (pl) *	2004-08-12	2009-04-30	Pfizer	Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
GB0418015D0 (en) *	2004-08-12	2004-09-15	Pfizer Ltd	New compounds

2009
- 2009-01-28 ES ES09708402T patent/ES2423991T3/es active Active
- 2009-01-28 PT PT97084024T patent/PT2303267E/pt unknown
- 2009-01-28 PL PL09708402T patent/PL2303267T3/pl unknown
- 2009-01-28 US US12/865,889 patent/US8222273B2/en not_active Expired - Fee Related
- 2009-01-28 KR KR1020107016846A patent/KR101422318B1/ko not_active Expired - Fee Related
- 2009-01-28 SI SI200930680T patent/SI2303267T1/sl unknown
- 2009-01-28 KR KR1020137015900A patent/KR20130087048A/ko not_active Withdrawn
- 2009-01-28 EP EP09708402.4A patent/EP2303267B1/en not_active Not-in-force
- 2009-01-28 RU RU2010132639/04A patent/RU2448966C1/ru not_active IP Right Cessation
- 2009-01-28 BR BRPI0907463A patent/BRPI0907463A2/pt not_active IP Right Cessation
- 2009-01-28 NZ NZ587094A patent/NZ587094A/en not_active IP Right Cessation
- 2009-01-28 WO PCT/IB2009/050351 patent/WO2009098612A2/en not_active Ceased
- 2009-01-28 CN CN2009801041294A patent/CN101939320B/zh not_active Expired - Fee Related
- 2009-01-28 MX MX2010008535A patent/MX2010008535A/es active IP Right Grant
- 2009-01-28 CA CA2712574A patent/CA2712574C/en not_active Expired - Fee Related
- 2009-01-28 AU AU2009211072A patent/AU2009211072B2/en not_active Ceased
- 2009-01-28 DK DK09708402.4T patent/DK2303267T3/da active
- 2009-02-02 JP JP2009021286A patent/JP5344942B2/ja not_active Expired - Fee Related
- 2009-02-03 AR ARP090100349A patent/AR070411A1/es unknown
- 2009-02-03 TW TW098103398A patent/TWI391391B/zh not_active IP Right Cessation
2010
- 2010-07-12 IL IL206948A patent/IL206948A/en not_active IP Right Cessation
- 2010-07-19 ZA ZA2010/05137A patent/ZA201005137B/en unknown
2013
- 2013-08-14 CY CY20131100704T patent/CY1114389T1/el unknown

Also Published As

Publication number	Publication date
IL206948A (en)	2014-12-31
CY1114389T1 (el)	2016-08-31
HK1147481A1 (zh)	2011-08-12
PT2303267E (pt)	2013-08-05
RU2010132639A (ru)	2012-02-10
EP2303267A2 (en)	2011-04-06
ZA201005137B (en)	2011-03-30
DK2303267T3 (da)	2013-09-02
US20110003848A1 (en)	2011-01-06
ES2423991T3 (es)	2013-09-26
EP2303267B1 (en)	2013-07-03
US8222273B2 (en)	2012-07-17
JP2009185028A (ja)	2009-08-20
AU2009211072A1 (en)	2009-08-13
NZ587094A (en)	2011-07-29
AU2009211072B2 (en)	2014-01-23
WO2009098612A3 (en)	2009-10-08
RU2448966C1 (ru)	2012-04-27
CN101939320B (zh)	2013-11-20
IL206948A0 (en)	2010-12-30
CA2712574A1 (en)	2009-08-13
CN101939320A (zh)	2011-01-05
KR101422318B1 (ko)	2014-07-22
TW200944524A (en)	2009-11-01
CA2712574C (en)	2014-01-07
SI2303267T1 (sl)	2013-09-30
TWI391391B (zh)	2013-04-01
WO2009098612A2 (en)	2009-08-13
KR20100108409A (ko)	2010-10-06
MX2010008535A (es)	2010-08-30
AR070411A1 (es)	2010-04-07
PL2303267T3 (pl)	2013-11-29
KR20130087048A (ko)	2013-08-05
JP5344942B2 (ja)	2013-11-20

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0907463A2 (pt)	2019-09-24	forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias
BRPI0909541A2 (pt)	2016-10-11	''método para tratamento de doenças inflamatórias do cólon''
AP2010005508A0 (en)	2010-12-31	Triazole derivatives useful for the treatment of diseases.
PL2321295T3 (pl)	2012-06-29	Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
IL192150A0 (en)	2008-12-29	Therapeutic agent for inflammatory bowel disease containing as active ingredient 2-amino-1,3-propanediol derivative, or method for treating inflammatory bowel disease
ZA200707591B (en)	2009-08-26	Dihyrothienopyrimidines for the treatment of inflammatory diseases
EP1988083A4 (en)	2009-11-11	triazole
IL210316A0 (en)	2011-03-31	Triazole derivative or salt thereof
BRPI0811103A2 (pt)	2014-12-09	Compostos triazol para tratamento de formação de biopelícula
IL205102A0 (en)	2010-11-30	1,3,5 - trisubstituted triazole derivative
IL206391A0 (en)	2010-12-30	Method for manufacturing heterocycle-substituted pyridine derivatives
DK1993589T3 (da)	2014-01-06	Behandlinger for neurologiske sygdomme
ZA200905700B (en)	2010-05-26	Triazole derivative as an HSP 90 inhibitor
BRPI0821357A2 (pt)	2017-05-23	derivados de oxadiazois de triazol
SI2121553T1 (sl)	2012-11-30	Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
IL200091A (en)	2013-05-30	Kittensan to treat infectious diseases of the nail
GB0700972D0 (en)	2007-02-28	Treatment of inflammatory disease
IL186904A0 (en)	2008-02-09	Novel compounds for treating inflammatory diseases
GB0720976D0 (en)	2007-12-05	Treatment of inflammatory disease
FI20070455A0 (fi)	2007-06-08	Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
IL209947A (en)	2014-07-31	Compounds for the treatment of corneal inflammation
BRPI1009145A2 (pt)	2016-04-19	método para a fabricação de derivado de benzodiazepina
ZA200707592B (en)	2008-10-29	Novel compounds for treating inflammatory diseases
IL204792A0 (en)	2010-11-30	Method for producing pyrazolinone derivative
IL194431A0 (en)	2011-08-01	Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases